Abstract
Summary
LPI (LP Information)' newest research report, the “Daratumumab Industry Forecast” looks at past sales and reviews total world Daratumumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Daratumumab sales for 2023 through 2029. With Daratumumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Daratumumab industry.
This Insight Report provides a comprehensive analysis of the global Daratumumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Daratumumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Daratumumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Daratumumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Daratumumab.
The global Daratumumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Daratumumab players cover Johnson＆Johnson. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Daratumumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
100mg Injection
400mg Injection
Segmentation by application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson＆Johnson
Key Questions Addressed in this Report
What is the 10-year outlook for the global Daratumumab market?
What factors are driving Daratumumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Daratumumab market opportunities vary by end market size?
How does Daratumumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Daratumumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Daratumumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Daratumumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Daratumumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Daratumumab.
The global Daratumumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Daratumumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Daratumumab players cover Johnson＆Johnson. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Daratumumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
100mg Injection
400mg Injection
Segmentation by application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson＆Johnson
Key Questions Addressed in this Report
What is the 10-year outlook for the global Daratumumab market?
What factors are driving Daratumumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Daratumumab market opportunities vary by end market size?
How does Daratumumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Daratumumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Daratumumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Daratumumab by Country/Region, 2018, 2022 & 2029
2.2 Daratumumab Segment by Type
2.2.1 100mg Injection
2.2.2 400mg Injection
2.3 Daratumumab Sales by Type
2.3.1 Global Daratumumab Sales Market Share by Type (2018-2023)
2.3.2 Global Daratumumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Daratumumab Sale Price by Type (2018-2023)
2.4 Daratumumab Segment by Application
2.4.1 Multiple Myeloma
2.4.2 Diffuse Large B Cell Lymphoma
2.4.3 Follicular Lymphoma
2.4.4 Mantle Cell Lymphoma
2.4.5 Other
2.5 Daratumumab Sales by Application
2.5.1 Global Daratumumab Sale Market Share by Application (2018-2023)
2.5.2 Global Daratumumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Daratumumab Sale Price by Application (2018-2023)
3 Global Daratumumab by Company
3.1 Global Daratumumab Breakdown Data by Company
3.1.1 Global Daratumumab Annual Sales by Company (2018-2023)
3.1.2 Global Daratumumab Sales Market Share by Company (2018-2023)
3.2 Global Daratumumab Annual Revenue by Company (2018-2023)
3.2.1 Global Daratumumab Revenue by Company (2018-2023)
3.2.2 Global Daratumumab Revenue Market Share by Company (2018-2023)
3.3 Global Daratumumab Sale Price by Company
3.4 Key Manufacturers Daratumumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Daratumumab Product Location Distribution
3.4.2 Players Daratumumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Daratumumab by Geographic Region
4.1 World Historic Daratumumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Daratumumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Daratumumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Daratumumab Market Size by Country/Region (2018-2023)
4.2.1 Global Daratumumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Daratumumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Daratumumab Sales Growth
4.4 APAC Daratumumab Sales Growth
4.5 Europe Daratumumab Sales Growth
4.6 Middle East & Africa Daratumumab Sales Growth
5 Americas
5.1 Americas Daratumumab Sales by Country
5.1.1 Americas Daratumumab Sales by Country (2018-2023)
5.1.2 Americas Daratumumab Revenue by Country (2018-2023)
5.2 Americas Daratumumab Sales by Type
5.3 Americas Daratumumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Daratumumab Sales by Region
6.1.1 APAC Daratumumab Sales by Region (2018-2023)
6.1.2 APAC Daratumumab Revenue by Region (2018-2023)
6.2 APAC Daratumumab Sales by Type
6.3 APAC Daratumumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Daratumumab by Country
7.1.1 Europe Daratumumab Sales by Country (2018-2023)
7.1.2 Europe Daratumumab Revenue by Country (2018-2023)
7.2 Europe Daratumumab Sales by Type
7.3 Europe Daratumumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Daratumumab by Country
8.1.1 Middle East & Africa Daratumumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Daratumumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Daratumumab Sales by Type
8.3 Middle East & Africa Daratumumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Daratumumab
10.3 Manufacturing Process Analysis of Daratumumab
10.4 Industry Chain Structure of Daratumumab
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Daratumumab Distributors
11.3 Daratumumab Customer
12 World Forecast Review for Daratumumab by Geographic Region
12.1 Global Daratumumab Market Size Forecast by Region
12.1.1 Global Daratumumab Forecast by Region (2024-2029)
12.1.2 Global Daratumumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Daratumumab Forecast by Type
12.7 Global Daratumumab Forecast by Application
13 Key Players Analysis
13.1 Johnson＆Johnson
13.1.1 Johnson＆Johnson Company Information
13.1.2 Johnson＆Johnson Daratumumab Product Portfolios and Specifications
13.1.3 Johnson＆Johnson Daratumumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Johnson＆Johnson Main Business Overview
13.1.5 Johnson＆Johnson Latest Developments
14 Research Findings and Conclusion